Get started
Work

Validation of Systemic Complement Signatures in the Progression of Chronic Obstructive Pulmonary Disease

Year: 2024
Type: article
DOI: 10.1164/rccm.202311-2059le
Authors: Katarina M. DiLillo, Lisa Ruvuna, Katherine A. Pratte, Karina A. Serban, Wassim W. Labaki, MeiLan K. Han, Christine M. Freeman, Russell P. Bowler, Jeffrey L. Curtis, Kelly B. Arnold
Institutions: University of Michigan, National Jewish Health, University of Florida Health, University of Florida, Michigan Medicine, VA Ann Arbor Healthcare System
Language: English
Field: Medicine
Open Access status: green
Funders: Amgen, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Ikaria, Chiesi Farmaceutici, COPD Foundation, Novartis Pharmaceuticals Corporation, Sunovion, Regeneron Pharmaceuticals, Mylan, Forest Research Institute, Grifols, National Institutes of Health, Genentech, National Heart, Lung, and Blood Institute
Awards: G1674756383, G2099663897, G2212190077, Understanding the Origins of Early COPD, G3027037974, G3868091120, G3999916299, G4578545918, G4749522346, G4975107759, G5195001291, G5258357286, G5434367891, G5510456481, (2 of 2) Genetic Epidemiology of COPD, SPIROMICS GIC Support, G6112557991, Identification of immune cell-cell communication networks and inflammatory pulmonary microenvironments associated with the progression of COPD, (1 of 2) Genetic Epidemiology of COPD, G7206313631, SPIROMICS II: Biological underpinnings of COPD heterogeneity and progression, G8354759825, G87279447, G8837091488, G8957911378, G9000091268, G9000228787
OpenAlex ID: W4402732521
FWCI: 0.842
Cites: 15
Cited by: 3
Related to: 10